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rEfraCtory to h1-antihiStaminES in turkEy
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Objectives: Omalizumab is a humanised anti-IgE recombinant monoclonal anti-
body approved in Turkey for treatment of chronic idiopathic (or spontaneous) urti-
caria (CIU) in patients resistant to standard treatment. We aimed to assess the 
cost-effectiveness of omalizumab compared with the standard care in the treatment 
of CIU patients in Turkey. MethOds: A Markov model of 10 years horizon was devel-
oped to estimate costs and outcomes associated with omalizumab 300mg/every 4 
weeks and standard of care for 24 weeks (SoC= licensed dose H1 antihistamines) 
using data from two phase III studies (ASTERIA I&II includes patients with CIU 
refractory to licensed dose of H1-antihistamines). The study was undertaken from 
a Turkish health care payer perspective. At the end of this period, omalizumab was 
stopped and background medication continued. Patients who have responded were 
retreated by the same strategy upon relapse (UAS7 ≥ 16 or ≥ 28). We used Urticaria 
Activity Score 7 (UAS7) to measure the outcome of the treatment and we used 
symptom free days (UAS7 ≤ 6) as the outcome measure in this cost effectiveness 
analysis. Resource utilization data were obtained via a Delphi panel. Unit costs 
were taken from the Social Security Institution’s official list. Costs and outcomes 
were evaluated over a lifetime and discounted at 3%. Results were presented as 
incremental cost/symptom free days. Results: The incremental symptom free 
days with omalizumab versus SoC was 27,965 days and the incremental cost was 
1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per 
symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed 
the robustness of the model results. cOnclusiOns: CIU affects the quality of life 
of patients and is associated with direct and indirect costs to payers and society. 
We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for 
patients with refractory CIU in Turkish setting.
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Objectives: To evaluate the efficacy of treatment with ranibizumab in a sample of 
Greek patients with nAMD. MethOds: In this observational, non-interventional, 
retrospective study, 194 cases with nAMD were enrolled from the Ophthalmology 
Department of “Attikon” hospital. Patients treated with ranibizumab for at least one 
year in one eye under routine clinical practice, and had at least one follow-up visit, 
were considered eligible. Patients participating in another study and/or were receiv-
ing pharmaceutical product containing VEGF inhibitors were excluded. Primary end-
points were the mean change in Best Corrected Visual Acuity (BCVA), and in Central 
retinal thickness (CRT), assessed by Optical Coherence Tomography. Results: 
The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen 
equivalent≈ 20/84; ETDRS letters≈ 57.7), which improved at final visit (≈14 months 
after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61.3), i.e. 
6,33% or approximately 3.7 ETDRS letters improvement (p< 0.001, r= 0.317) with 4.9 
ranibizumab injections overall (4.3 injections/year). CRT similarly improved, as it 
decreased by 28.4%, from 290.31 to 207.77 μ m (p< 0.001, r= 0.683). An extra ranibi-
zumab injection per eye per year, increased the odds of an at least 0.1 increase in 
BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 
increase by 15.7% (95%CI 1.013-1.322). cOnclusiOns: Ranibizumab provides sig-
nificant benefit in patients with nAMD under routine clinical practice by improving 
BCVA and reducing CRT, benefit which may be more important in a more frequent 
dosing regimen.
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Objectives: Background: The project focused on the preventive use, effectiveness 
and the better knowledge about the potential effects and mechanisms of dress-
ings. Aims: To improve the effectiveness of wound care, to prevent effectively the 
appearance of pressure ulcers during hospitalization. MethOds: During 2 months 
of the project 80 patients of 3 active and 2 chronic care departments were involved, 
treatment of 84 pressure ulcers of 46 patients occurred. After the health check the 
attachment of dressings and the wound management were carried out according 
to the protocols and were documented on special datasheets. Subsequently, the 
checking and processing of questionnaires – continuing the monitoring of patient 
pathways – were done. Results: Pressure ulcers did not develop in case of 79% of 
the patients after prevention, effectiveness of targeted prevention reached 95.5%. 
The incidence of decubitus fell by 1.6-1.7 % in the project (formation rate was 58.8-
90.9 % lower in average). In the background of successful prevention min. 3-day use 
was observed, but even use of 1-1 preventive dressing was effective. The average 
length of wound care was14 days, frequency was 8.2 times/patient. The healed or 
recovering wounds were more frequently treated, but rather for more days, how-
ever, their treatment cost less than the average and those wounds which were not 
healing. cOnclusiOns: Wound care starts with prevention. The quality of wound 
care should not decrease after the patient’s discharge, the home follow-up would 
be essential, nevertheless its “best practices” has not spread widely in Hungary yet. 
In the short term Decubitus Team doctors should be involved in patients’ discharge 
planning, however in the long term creation of a so-called Wound Care Centre could 
offer a sustainable solution. Hereinafter controlled trials of higher number of cases 
could prove the cost-effectiveness of intelligent dressings in wider aspects of the 
health care system.
tobacco tax is important as a source of revenue. The objectives of this research is to 
quantitatively assess about how general public value several aims of tobacco policy 
and the amount of tax revenue and to estimate “ideal” tobacco price where the price 
elasticity of tobacco consumption is given. MethOds: We conducted a web-based 
survey from 9-15, Aug 2012 including a discrete choice experiment (DCE) to elicit 
general public’s preference for targeted smoking rate, tax revenue, tobacco policy for 
the younger generation and the usage of tax. Then, we numerically forecast general 
publics’ support rate of a tobacco policy as a function of tobacco price where price 
elasticity is given. Results: 1,077 completed questionnaires and were eligible for 
analysis. They statistically prefer the tobacco policy which results in lower prevalence 
of smokers, higher tax revenue, targeted for young people and tax revenue is used for 
general purposes. Given the price elasticity of 0.3, 0.4 and 0.5, highest tobacco price, 
which acquire the highest support from general public, was around JPY871 (EUR6.2), 
JPY555 (EUR4.0) and JPY454 (EUR3.2), respectively. cOnclusiOns: The present price 
of cigarette per one pack is around JPY460 (EUR 3.3). When smokers are highly respon-
sive to price elevation and are successfully quit after the elevation, present price of 
cigarette is suitable when we consider public’s preference for tax revenue as well as 
normal policy measures. Rooms for further price elevations depends on the price 
elasticity of cigarette consumption.
SEnSory SyStEmS diSordErS – Clinical outcomes Studies
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Objectives: To indirectly compare the efficacy of approved treatments for 
macular oedema secondary to branch retinal vein occlusion (BRVO). MethOds: 
Randomized, controlled trials (RCTs) evaluating the efficacy at month 6 (or month 
12) of at least two of ranibizumab 0.5mg pro re nata (after 6 monthly doses), afliber-
cept 2.0mg monthly, dexamethasone implant (retreatment interval ≥ 6 months), 
laser photocoagulation or sham were identified from a published systematic 
review, congress abstracts, clinicaltrials. gov and Novartis data on file. Outcomes of 
interest were the mean change in best-corrected visual acuity (BCVA, measured as 
Early Treatment Diabetic Retinopathy Study letters), and the percentage of patients 
gaining ≥ 15 letters. For two studies, the standard deviation around mean BCVA 
gain was estimated. A Bayesian network meta-analysis with random treatment 
effects was used to compare mean BCVA gains and odds ratios (ORs) for gaining 
≥ 15 letters. Results: The analysis included seven RCTs. Patient-level data for 
three ranibizumab trials were re-analysed to match key inclusion criteria (BCVA 
and duration of disease at baseline) from aflibercept studies. Statistically signifi-
cant (p< 0.05) BCVA letter gains were found for ranibizumab monotherapy (+11.6), 
ranibizumab plus laser combination therapy (+10.1) and aflibercept (+10.1) versus 
laser, and for ranibizumab monotherapy versus dexamethasone (+8.0). ORs versus 
laser for gaining ≥ 15 letters were 3.24 (95% credible interval, 1.03–12.56; p< 0.05) 
and 3.07 (0.63–14.8) for ranibizumab monotherapy and aflibercept, respectively. 
Mean BCVA letter gains were numerically higher with ranibizumab monotherapy 
compared with aflibercept (+1.5 letters [-5.3–8.8]; OR for gaining ≥ 15 letters, 1.06 
[0.16–8.94]). The probability of being the most efficacious treatment based on let-
ters gained was 57% for ranibizumab, 15% for ranibizumab plus laser and 28% for 
aflibercept. cOnclusiOns: The analysis confirms the superiority of ranibizumab 
over dexamethasone implant and laser therapy, and shows that ranibizumab has 
the highest likelihood of being the most efficacious treatment for BRVO.
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Objectives: Recently, advanced treatments such as topical growth factors, bio-
logical dressings, and tissue engineered products have been developed in order 
to promote healing as well as decrease the time to healing of chronic leg ulcers. 
Nevertheless, if standard care fails, there is no widely accepted, easy to use second-
line treatment primarily because most of these advanced treatments are expensive 
and need further evidence of effectiveness in everyday clinical practice. The purpose 
of our study was to assess the effectiveness of a new acellular synthetic matrix 
(ASM) as an adjunct to standard care, using healing time as endpoint, in venous and 
mixed leg ulcers in German everyday clinical practice. MethOds: Prospective data 
on venous and mixed leg ulcers from a safety and effectiveness study on an acellular 
synthetic matrix was compared retrospectively to matched data from a German 
Registry of Chronic Wounds (DRCW) database containing German patients with 
equivalent leg ulcer disease, patient age and gender, baseline wound area, wound 
duration, same outcome measures, and comparable follow-up periods. The outcome 
of interest was healing time over 12-weeks of treatment. Results: Analysis using 
Kaplan Meier survival curves showed a mean of 73.1 days (95% CI: 66.4 - 79.9 days) 
to healing for acellular synthetic matrix treated ulcers, in comparison to 92.2 days 
(95% CI: 87.1 – 97.2 days) for equivalent ulcers treated in everyday clinical practice 
in Germany (Log rank test χ 2 11.46, p= 0.001). cOnclusiOns: Results from this 
study predict a highly significant effect of a new acellular synthetic matrix as an 
adjunct to standard care in the repair of venous and mixed leg ulcers. The predic-
tive model may be useful in determining expected effectiveness of the acellular 
synthetic matrix in the treatment of venous and mixed leg ulcer patients treated 
in everyday clinical practice in Germany.
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thE EPidEmiology of mEdiCal trEatmEnt for glauComa and oCular 
hyPErtEnSion in gErmany
Ernst F.
Santen GmbH, Munich, Germany
Objectives: The purpose of this study is to review the epidemiology and the treat-
ment paradigm of German glaucoma population and to assess the frequency of 
switches from monotherapy to second- or third line combination therapy in primary 
open angle glaucoma (POAG) patients. Glaucoma is the second leading cause of 
blindness globally. The newly published EGS guidelines state that if the first choice 
monotherapy is well tolerated and has effective intra ocular pressure (IOP) lowering 
but has not succeeded in reaching the target pressure, the addition of a second drug 
should be considered. MethOds: German patient databases were searched in the 
following areas: glaucoma prevalence and incidence studies in German popula-
tion as well as treatment paradigm in glaucoma patients. Results: Our analysis 
underlines the high number of glaucoma patients in Germany and the relevance of 
this disease for the German health care system. The study also demonstrates that 
a considerable number of glaucoma patients do not reach IOP target under mono-
therapy and have to be treated with a combination therapy. In general, treatment 
with a combination of agents of different classes is associated with superior IOP 
lowering efficacy. With an increasing number of available fixed dose combination 
products, more options become available for combination therapy of glaucoma 
patients. cOnclusiOns: Glaucoma care needs to be given high priority in public 
health programs. Especially treatment options for glaucoma patients in need for a 
combination therapy should be in the focus of health care system decision makers 
as well as further research in glaucoma clinical trials and clinical care.
SEnSory SyStEmS diSordErS – Cost Studies
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a uS hoSPital EConomiC imPaCt modEl for oritavanCin in abSSSi 
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Objectives: It is estimated that acute bacterial skin and skin structure infections 
(ABSSSI) account for about 10% of hospital admissions in the US. Analyses of hos-
pital claims indicate 74% of ABSSSI admissions involve empiric treatment with 
methicillin-resistant Staphylococcus aureus (MRSA) active antibiotics. Hospitalization 
costs could be reduced if moderate-severe ABSSSI patients were treated to a greater 
extent in the observational unit followed by discharge to outpatient parenteral 
antibiotic therapy (OPAT). Oritavancin is a novel single-dose regimen, intrave-
nous lipoglycopeptide antibiotic for ABSSSIs caused by gram-positive bacteria, 
including MRSA. The aim of our analysis was to quantify the economic value of 
using oritavancin for ABSSSI patients at risk of MRSA from a US hospital perspec-
tive. MethOds: A decision analytic model based on current clinical practice was 
developed to estimate the economic value of decreased hospital resources by using 
oritavancin. Utilization of antibiotics was informed by analysis of the Premier hos-
pital database. Demographic and clinical data were derived from a targeted litera-
ture review. ER, observation, laboratory, administration costs were from Medicare 
National Limitation amounts. Drug costs were 2014 wholesale acquisition costs. To 
estimate the economic impact of reducing resources using oritavancin we set its 
price to $0. Results: For a hypothetical US hospital treating 1,000 ABSSSI patients 
eligible for IV MRSA antibiotics/year, the administration of oritavancin in 25.75% of 
patients facilitates shifting patients to the OPAT setting (441 to 561 patients) with 
a total annual economic impact of $2,752K. Inpatient and outpatient costs were 
reduced by $2,543K and $209K, respectively. Inpatient cost savings were derived from 
a reduction in hospitalizations and lower administration burden drove decreased 
OPAT costs. cOnclusiOns: Using oritavancin in moderate-severe ABSSSI patients, 
including those at risk of MRSA, is estimated to deliver an estimated cost reduc-
tion of $2,752/patient by shifting patient care to the OPAT setting, and decreasing 
resource utilization.
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Objectives: To examine the economic impact and independent determinants of 
visual impairment (VI) in Singapore. MethOds: 100 patients with VI associated 
with the most common eye diseases were recruited from the Singapore National Eye 
Centre. VI was classified as mild and moderate/severe VI based on the presenting 
visual acuity (VA) in the better-seeing eye. Medical costs (MC) and loss of productiv-
ity (LP) in the patients and their families were estimated based on the center’s billing 
data and self-reported data, respectively. LP was calculated for working patients 
based on absenteeism due to VI. Linear regression models were used to assess the 
association between costs and VI, generic (EQ-5D), and vision-specific quality of 
life (VF-14). Results: The median (range) age of participants was 73.0 years old 
(47.0-92.0). The proportion of male was 48.0% and the median (range) presenting 
VA was 0.54 (0.30-2.00). The yearly median (range) MC and LP were S$1.53K (S$0.13-
S$83.59K) and S$0 (S$0-S$7.62K) per person, respectively. The yearly MC for those 
with mild VI (S$3.50K) was significantly lower than those with moderate/severe VI 
(S$5.21K) (P< 0.0001). The yearly MC in participants reporting full health or better 
vision function were lower than those not in full health or better vision function 
(e. g. MC for participants in full health= S$2.96K; MC for participants not in full 
health= S$5.19K; P< 0.0001). After adjusting for socio-demographic characteristics, 
the association between MC and VI, EQ-5D and VF-14 remained the same. LP had a 
similar association with EQ-5D and VF-14 with or without adjustment; however, LP 
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Objectives: To review the literature evaluating the clinical efficacy of Fumaderm 
(FAE) in patients suffering from psoriasis and psoriatic arthritis. MethOds: 
Systematic literature search in electronic databases (MEDLINE, Cochrane and 
Embase) was performed (from inception to March 14,2014). Results were presented 
by narrative synthesis including a quality assessment using Jadad scale. Results: 
Three randomized controlled trials were included (Fallah Arani 2011, Altmeyer 1994, 
Peeters 1992). Quality of studies ranged from 3 to 4 points. Observation period 
was 16 weeks for all studies. One open-label study comparing FAE with metho-
trexate (MTX) in moderate to severe chronic plaque psoriasis was identified. The 
primary efficacy endpoint was the difference in mean change from baseline in 
Psoriasis Area and Severity Index (PASI). After 12 weeks of treatment the mean 
PASI (± SD) decreased to 10.5 ± 6.7 compared with starting value of 18.1 ± 7.0 in 
patients treated with FAE and to 6.7 ± 4.5 compared to starting value of 14.5 ± 
3.0 in patients treated with MTX. The absolute difference between groups (FAE 
vs. MTX) in the mean values was 1.4 (95%CI: 2.0; 4.7) and wasn’t statistically sig-
nificant (p = 0.417). In the remaining two double-blind studies the efficacy and 
safety of Fumaderm was assessed against the placebo. One study shows that in 
psoriasis vulgaris population the mean PASI in FAE group decreased from 21.53 at 
baseline to 10.77, whereas in placebo group mean PASI has not changed (p< 0.0001) 
after 16 weeks of treatment. Moreover, the results of study in psoriatic arthritis 
population revealed that FAE significantly (p< 0.04) decrease joint pain compared 
to placebo. cOnclusiOns: The results revealed that FAE and MTX have similar 
clinical efficacy in the treatment of patients with moderate to severe psoriasis. 
Moreover, FAE is more effective than placebo in the treatment of psoriasis vulgaris 
and psoriatic arthritis.
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Objectives: To evaluate the knowledge and perception of medical and phar-
macy students toward the usage of sunblock as skin protection against ultraviolet 
(UV). MethOds: This cross-sectional study was conducted among the undergradu-
ate final year medical and pharmacy students at the International Islamic University 
Malaysia (IIUM). Validated questionnaire were used to collect the data. The question-
naires were distributed to 134 students from medicine and 100 pharmacy students. 
Descriptive and inferential statistics are used whenever appropriate. Results: 
Overall, 161 participants out of a total of 234 completed the questionnaire with 
101 medical students (75.4%) and 60 pharmacy students (60.0%). Majority of the 
respondents were female 64 (63.4%) and 37 (36.6%) were male. The median of knowl-
edge scores of the final year medical students was significantly lower than the 
final year pharmacy students (p< 0.01). There is no significant differnce between 
the knowledge of the female and male students (Mann Whitney U Test value = 
0.27, p< 0.01). This study reported that 24 (39.3 %) of pharmacy students were influ-
enced by the media to use sunblock whereas 35 (34.7%) of medical students had the 
highest influence from friends to use sunblock. However, this study showed there 
was no significant difference in the perception of pharmacy and medical studnets 
p= 0.020. cOnclusiOns: In conclusion, the knowledge of pharmacy students is 
significantly higher than the knowledge of medical students had on the usage of 
sunblock. Both medical and pharmacy students have the same level of perception 
towards the usage of sunblock.
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Gilligan A.M., Waycaster C.
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
Objectives: Venous leg ulcers (VLUs) are a debilitating condition for patients with 
venous insufficiency. Compression therapy is the standard care for treatment of 
VLU; however the success rate is approximately 50% at 6 months. Clinical trials 
with cellular/tissue derived products (CTPs) have shown promising efficacy for 
the treatment of VLU. The objective was to identify patient and clinical character-
istics in the VLU population and examine patterns of CTP utilization. MethOds: 
Retrospective, de-identified electronic medical records from 2007-2013 were 
extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records 
from 96 hospital-based outpatient wound centers. Patient, wound and encounter 
level characteristics were examined. CTPs of interest included extracellular matrix 
(ECM), human skin equivalent (HSE), and living skin equivalent (LSE). Results: 
A total of 9,091 patients, 25,734 wounds, and 222,666 encounters for VLU were 
identified. The majority of patients was male (50.5%), Caucasian (74.1%), and 
reported Medicare as their primary insurance (53.4%). The average age was 68.9 
(SD= 14.6) and the average number of physician visits was 17.7 (SD= 22.5). The mean 
wound surface area was 20.1cm2 (SD= 83.4). The overall average wound duration 
was 5.8 months (SD= 26.7). Of the 25,734 wounds, approximately 7.1% received 
ECM (3.4%), HSE (3.5%), or LSE (0.2%). The average number of applications for ECM 
was 2.7 (SD= 2.8), 0.6 (SD= 1.3) for HSE, and 3.1 (SD= 3.3) for LSE. Wounds treated 
with CTPs were, on average, several months older: 12.5, 13.7, and 11.1 months for 
ECM, HSE, and LSE, respectively. Overall average wound treatment time was 2.9 
months (SD= 4.8). However, treatment time was substantially longer with CTP 
utilization with an average time of 9.6, 9.7, and 7.5 months for ECM, HSE, and LSE, 
respectively. cOnclusiOns: CTP utilization was relatively low within outpatient 
wound centers. Results from this analysis indicate that health care providers are 
using CTPs on older, more difficult-to-heal VLUs.
